Hims & Hers Scales Telehealth Model With Peptides and Partnerships
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Hims & Hers Scales Telehealth Model With Peptides and Partnerships” inside PodZeus.
Hims & Hers is positioning itself as the Netflix of healthcare by leveraging speed, convenience, affordability, and a growing focus on personalized medicine—starting with its exclusive ownership of a FDA-compliant peptide manufacturing facility. As the FDA prepares to reclassify 12 peptides from restricted Category 2 to accessible Category 1 in July 2026, Hims & Hers stands to capture massive first-mover advantage, with its CS Bio facility in Menlo Park enabling safe, scalable production. This infrastructure, combined with a strategic partnership with Novo Nordisk—once a legal adversary—marks a pivotal shift toward a pharmaceutical-telehealth ecosystem where Hims & Hers becomes the distribution and marketing engine for branded drugs. The company’s $1 billion in interest-free convertible debt is fueling rapid international expansion via turnkey acquisitions, allowing it to bypass years of ground-up development and dominate fragmented global markets. The result? A vertically integrated healthcare platform poised to monopolize the future of digital medicine. The episode reveals that Hims & Hers isn’t just riding the peptide trend—it’s building the infrastructure to own it. With FDA reclassification timelines set for July 2026 and February 2027, the company has a clear path to control both supply and demand. Its partnership with Novo Nordisk is not just a revenue play but a strategic signal: pharmaceutical giants now see telehealth platforms as essential distribution partners.
Hims & Hers owns the only public U.S. peptide manufacturing facility (CS Bio), giving it exclusive access to FDA-compliant peptide production.
The FDA is scheduled to reclassify 12 peptides from Category 2 to Category 1 in July 2026, unlocking legal, scalable distribution.
Hims & Hers’ $1 billion in interest-free convertible debt enables rapid international expansion via turnkey acquisitions.
The partnership with Novo Nordisk marks a strategic pivot from legal rivalry to a pharmaceutical-telehealth alliance.
Hims & Hers is evolving into a distribution and marketing engine for branded drugs, not just a direct-to-consumer brand.
…and 3 more takeaways available in PodZeus
Hims & Hers as the Netflix of Healthcare
“What Netflix did much better than Blockbuster was that they were faster. What required you know sometimes two to four trips was just instant. You could do it from your home.”
Peptides and the FDA Re-Classification Timeline
“July 23rd and 24th is when the FDA meets. This first meeting, they're going to talk about five out of 12 peptides to move from Category 2 to Category 1.”
Hims & Hers’ Exclusive Peptide Manufacturing Advantage
“There's only one way to go long, peptides in the public markets, and that's through Hims & Hers.”
Strategic Partnership with Novo Nordisk
The shift from legal rivalry to collaboration with Novo Nordisk signals a new era where Hims & Hers becomes the distribution and marketing partner for major pharma brands.
Global Expansion via Turnkey Acquisitions
With $1 billion in interest-free debt, Hims & Hers is rapidly expanding internationally by acquiring existing telehealth platforms instead of building from scratch.
“There's only one way to go long, peptides in the public markets, and that's through HIMSS. And”
“and done, we're going to monopolize this industry and we're going to be top dog in a very sort of fragmented space.”
“What Netflix did much better than Blockbuster was that they were faster. What required you know sometimes two to four trips was just instant. You could do it from your home.”
Host
Guest
Hims & Hers
organization
Raul Shah
person
FDA
organization
Novo Nordisk
organization
CS Bio
organization
Doc Shaw Financial
organization
Hempstead
organization
Leifemess
organization
Neum
organization
Eucalyptus
organization
The Big 3: VST, C, AAPL
Schwab Network • 13m • 3/31/2026
Kudla on Commodities, Defense, and Market Upside
Schwab Network • 10m • 3/31/2026
The Big 3: SBUX, XLE, AAPL
Schwab Network • 15m • 4/1/2026
Nasdaq 100: Looking Past Volatility to Fundamental Strength
Schwab Network • 13m • 4/1/2026
How to Manage Your 401(k) During Market Volatility
Schwab Network • 10m • 4/1/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Hims & Hers Scales Telehealth Model With Peptides and Partnerships” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime